531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

 

 

Start SIP in VENMAX

Start SIP

Performance

  • Low
  • ₹24
  • High
  • ₹27
  • 52 Week Low
  • ₹8
  • 52 Week High
  • ₹37
  • Open Price₹24
  • Previous Close₹26
  • Volume1,177

Investment Returns

  • Over 1 Month -6.8%
  • Over 3 Month + 7.74%
  • Over 6 Month + 5.07%
  • Over 1 Year + 235.09%

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 40.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 14
  • P/B Ratio
  • Average True Range
  • 1.9
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.38
  • RSI
  • 37.11
  • MFI
  • 4.98

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹26.74
+ 1.24 (4.86%)
pointer
  • Bearish Moving Average 10
  • Bullish Moving Average 6
  • 20 Day
  • ₹27.98
  • 50 Day
  • ₹27.50
  • 100 Day
  • ₹26.83
  • 200 Day
  • ₹24.57

Resistance and Support

25.67 Pivot Speed
  • R3 26.33
  • R2 26.17
  • R1 25.83
  • S1 25.33
  • S2 25.17
  • S3 24.83

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 3.06 Cr. on a trailing 12-month basis. An annual revenue growth of 830% is outstanding, Pre-tax margin of -2% needs improvement, ROE of -0% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -18% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 92 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 77 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-09-02 Amalgamation & A.G.M.
2025-08-16 Others Inter alia, to consider and approve 1. Allotment of Equity Shares pursuant to conversion of Convertible Equity Share Warrants.
2025-07-23 Quarterly Results
2025-05-09 Audited Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

23.13%
0%
65.36%
11.51%

About Venmax Drugs & Pharmaceuticals

  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹26 As on 11 December, 2025 | 14:15

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹14 Cr As on 11 December, 2025 | 14:15

The P/E ratio of Venmax Drugs & Pharmaceuticals is 40.6 As on 11 December, 2025 | 14:15

The PB ratio of Venmax Drugs & Pharmaceuticals is -21.2 As on 11 December, 2025 | 14:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23